Kidney acidosis drug study pulled before it began
NCT ID NCT03831152
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study was designed to check the long-term safety and effectiveness of a drug called ADV7103 in people with primary distal renal tubular acidosis, a rare kidney problem that leads to too much acid in the blood. It planned to include people who had been in an earlier study, as well as new patients in Europe aged 6 months and older, and infants under 6 months. However, the study was withdrawn before any participants were enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACIDOSIS, RENAL TUBULAR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of South Florida Pediatric Infectious Diseases
Tampa, Florida, 33606, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.